A Radioimmunoassay Technique for Digoxin in Postmortem Blood

    Volume 19, Issue 4 (October 1974)

    ISSN: 0022-1198


    Published Online: 1 October 1974

    Page Count: 13

    Phillips, AP
    Senior scientific officer, Home Office Central Research Establishment, Reading, Berkshire

    (Received 8 June 1973; accepted 6 December 1973)


    In spite of the availability of purified digitalis fractions such as digoxin, treatment of congestive heart failure and arrhythmias with cardiac glycosides is attended by considerable risk of toxicity and even death. Beller et al [1] estimate that toxicity results in 8–20 percent of hospital patients taking digoxin, with a subsequent mortality of 7–50 percent. The development of a radioimmunoassay sufficiently sensitive to quantitate digoxin in serum or plasma during therapy [2] might be expected to improve the control of therapy in patients with absorption or excretion abnormalities, and Smith and Haber [3] reported that more than 85 percent of toxic cases could be distinguished from nontoxic ones by the plasma digoxin concentrations. However, more recently, Fogelman et al [4] found little increase in plasma digoxin in toxicity; mean plasma concentrations were 1.69 ± 1.29, 1.61 ± 0.79, and 1.41 ± 1.09 ng/ml in groups classified as toxic, possibly toxic, and nontoxic. The extensive overlap of the digoxin concentrations in these three groups suggests that sensitivity to digoxin is the main factor in determining the onset of toxicity.

    Paper ID: JFS10482J

    DOI: 10.1520/JFS10482J

    ASTM International
    is a member of CrossRef.

    Title A Radioimmunoassay Technique for Digoxin in Postmortem Blood
    Symposium , 0000-00-00
    Committee E30